Programme

4 June 2019
BMA House, London

 

View Programme

Book Now

20645-hsj-life-sciences-forum-logo.png

HSJ Life Sciences Forum
Innovating to deliver improved patient services and outcomes

BMA House, London • 4 June 2019

DRAFT PROGRAMME

09:00 Registration & Refreshments
09:45

Chair’s Opening Remarks

Alastair McLellan, Editor, HSJ

10:00

Opening Keynote Plenary
Baroness Blackwood, Parliamentary Under Secretary of State for Health, Department of Health and Social Care

10.30

Panel Discussion: What the NHS long-term plan means for industry
Dr Sam Roberts, Director of Innovation, Research and Life Sciences Group, NHS England
Mike Thompson, Chief Executive, ABPI
James Roach, Director, West Essex ICP

11.15

Morning Refreshments & Networking

 

Innovation & Digital

Governance & Regulation
11.30

Using data to support innovation

  • Learn how Local Health and Care Records (LHCRE) are being used in regional hubs
  • Find out how new digital technologies will be evaluated in future
  • Gain insight into how data flows are being utilised and what rules are being enforced

Professor Andrew Morris, Director, Health Data Research UK

Understanding industry’s role in STPs and ICSs

  • Hear first-hand the plans being created at a local level through the STP process
  • Learn what challenges STPs are facing and how industry could support
  • Take part in a discussion to find out how industry can better support STPs

Dr Phil Richardson, Chief System Integration Officer, Dorset ICS

12.20

Networking Lunch

13.20

Unleashing the potential of genomics and personalised medicine

  • Receive an update on 100,000 Genomes project
  • How the is project making the UK an attractive investment destination for life sciences
  • Learn how data is being used to accelerate treatments and enable efficient drug research

Joanne Hackett, Chief Commercial Officer, Genomics England
Professor Dame Sue Hill, Chief Scientific Officer, NHS England
Sue Bailey, Strategic Partnership & Early Asset Director, BMS

Removing barriers: evolving the role of regulation

  • Understand how the role of MHRA is changing and what this means for industry
  • Learn about the successes from the NICE fast track programme
  • Find out how NHS England’s commercial team has improved access to new drugs

Meindert Boysen, Centre for Health Technology Evaluation Director, NICE
Dr Ian Hudson, Chief Executive, MHRA

14.10

Afternoon Refreshments & Networking

14.30

Voluntary scheme for branded medicines pricing and access: What the final agreement means for industry and the NHS

Steve Oldfield, Chief Commercial Officer, Department of Health and Social Care
Louise Houson, Managing Director UK, MSD

15.10

Specialised Commissioning: Improving access to new treatments in rare diseases

Blake Dark, NHS Commercial Medicines Director, NHS England

15.40

Panel Discussion: Next steps for implementing the Life Sciences Industrial Strategy in post-Brexit Britain

Tamsin Berry, Deputy Director, Office for Life Sciences

Nicole Mather, Non-Executive Director, Health Research Authority

16.15

Chair’s Closing Remarks

Alastair McLellan, Editor, HSJ

16.30

Networking Reception

By continuing to use the site you agree to our cookies policy. Accept